A theme covering the continuation of clinical and preclinical research on multiple drug candidates, including the F351 Phase 2 trial in China and the RP pre-pilot trial ahead of Phase 3. Although the spread of COVID-19 caused temporary suspensions and delays, Cullgen's development programs progressed generally as planned.